Pericyte-targeting drug delivery and tissue engineering

International Journal of Nanomedicine

Volumn 11, Issue , 2016, Pages 2397-2406

  Kang, Eunah ^a   Shin, Jong Wook ^b  

^a School of Chemical Engineering and Material Science   (South Korea)

^b Chung Ang University   (South Korea)

Author keywords

Angiogenesis; Pericyte targeting drug delivery; Pericytes; Platelet derived growth factor; Tissue engineering; Vascular remodeling

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; B RAF KINASE; BEVACIZUMAB; BONE MORPHOGENETIC PROTEIN 4; CD146 ANTIGEN; CD31 ANTIGEN; COLLAGEN TYPE 1; DESMIN; GLUTAMYL AMINOPEPTIDASE; IMATINIB; MICROSOMAL AMINOPEPTIDASE; MYOSIN; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BB; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; RGS PROTEIN; RGS5 PROTEIN; SU 668; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; ANTINEOPLASTIC AGENT; PEPTIDE;

CANCER INHIBITION; CELL DIFFERENTIATION; CELL FUNCTION; CELL INTERACTION; CELL JUNCTION; CELL MIGRATION; CELL PROLIFERATION; DRUG DELIVERY SYSTEM; DRUG ELUTING STENT; ENDOTHELIUM CELL; HUMAN; NANOENCAPSULATION; NONHUMAN; PERICYTE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; STEM CELL; TISSUE ENGINEERING; TUMOR MICROENVIRONMENT; VASCULAR REMODELING; ANIMAL; CAPILLARY; CYTOLOGY; DRUG EFFECTS; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; PROCEDURES;

ANIMALS; ANTINEOPLASTIC AGENTS; CAPILLARIES; DRUG DELIVERY SYSTEMS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDES; PERICYTES; SIGNAL TRANSDUCTION; STEM CELLS; TISSUE ENGINEERING; TUMOR MICROENVIRONMENT; VASCULAR REMODELING;

EID: 84971574776     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S105274     Document Type: Review

References (56)

1. Cheng L, Huang Z, Zhou W, et al. Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell. 2013;153:139-152.
2. Armulik A, Abramsson A, Betsholtz C. Endothelial/pericyte interactions. Circ Res. 2005;97:512-523.
3. Guichet PO, Guelfi S, Teigell M, et al. Notch1 stimulation induces a vascularization switch with pericyte-like cell differentiation of glioblastoma stem cells. Stem Cells. 2015;33:21-34.
4. Sims DE. The pericyte - a review. Tissue Cell. 1986;18:153-174.
5. Sims DE. Diversity within pericytes. Clin Exp Pharmacol Physiol. 2000; 27:842-846.
6. Nishihara H. Human pathological basis of blood vessels and stromal tissue for nanotechnology. Adv Drug Deliv Rev. 2014;74:19-27.
7. Kelly-Goss MR, Sweat RS, Stapor PC, Peirce SM, Murfee WL. Targeting pericytes for angiogenic therapies. Microcirculation. 2014;21:345-357.
8. Fakhrejahani E, Toi M. Tumor angiogenesis: pericytes and maturation are not to be ignored. J Oncol. 2012;2012:261750.
9. Ribatti D, Nico B, Crivellato E. The role of pericytes in angiogenesis. Int J Dev Biol. 2011;55:261-268.
10. Chen WC, Baily JE, Corselli M, et al. Human myocardial pericytes: multipotent mesodermal precursors exhibiting cardiac specificity. Stem Cells. 2015;33:557-573.
11. Berger M, Bergers G, Arnold B, Hämmerling GJ, Ganss R. Regulator of g-protein signaling-5 induction in pericytes coincides with active vessel remodeling during neovascularization. Blood. 2005;105: 1094-1101.
12. Tigges U, Komatsu M, Stallcup WB. Adventitial pericyte progenitor/mesenchymal stem cells participate in the restenotic response to arterial injury. J Vasc Res. 2013;50:134-144.
13. Dore-Duffy P, Owen C, Balabanov R, Murphy S, Beaumont T, Rafols JA. Pericyte migration from the vascular wall in response to traumatic brain injury. Microvasc Res. 2000;60:55-69.
14. Acharya G, Park K. Mechanisms of controlled drug release from drug-eluting stents. Adv Drug Deliv Rev. 2006;58:387-401.
15. Shepro D, Morel NM. Pericyte physiology. FASEB J. 1993;7: 1031-1038.
16. Kim J, Chung M, Kim S, Jo DH, Kim JH, Jeon NL. Engineering of a biomimetic pericyte-covered 3D microvascular network. PLoS One. 2015;10:e0133880.
17. Andrejecsk JW, Cui J, Chang WG, Devalliere J, Pober JS, Saltzman WM. Paracrine exchanges of molecular signals between alginate-encapsulated pericytes and freely suspended endothelial cells within a 3D protein gel. Biomaterials. 2013;34:8899-8908.
18. Aguilera KY, Brekken RA. Recruitment and retention: factors that affect pericyte migration. Cell Mol Life Sci. 2014;71:299-309.
19. Rajkumar VS, Shiwen X, Bostrom M, et al. Platelet-derived growth factor-beta receptor activation is essential for fibroblast and pericyte recruitment during cutaneous wound healing. Am J Pathol. 2006; 169:2254-2265.
20. Stratman AN, Schwindt AE, Malotte KM, Davis GE. Endothelial-derived Pdgf-Bb and Hb-Egf coordinately regulate pericyte recruitment during vasculogenic tube assembly and stabilization. Blood. 2010; 116:4720-4730.
21. Li Q, Puro DG. Adenosine activates Atp-sensitive K(+) currents in pericytes of rat retinal microvessels: role of A1 and A2a receptors. Brain Res. 2001;907:93-99.
22. Park F, Mattson DL, Roberts LA, Cowley AW Jr. Evidence for the presence of smooth muscle alpha-actin within pericytes of the renal medulla. Am J Physiol. 1997;273:R1742-R1748.
23. Skalli O, Pelte MF, Peclet MC, et al. Alpha-smooth muscle actin, a differentiation marker of smooth muscle cells, is present in microfilamentous bundles of pericytes. J Histochem Cytochem. 1989;37: 315-321.
24. Nico B, Ennas MG, Crivellato E, et al. Desmin-positive pericytes in the chick embryo chorioallantoic membrane in response to fibroblast growth factor-2. Microvasc Res. 2004;68:13-19.
25. Stallcup WB, You WK, Kucharova K, Cejudo-Martin P, Yotsumoto F. NG2 Proteoglycan-dependent contributions of pericytes and macrophages to brain tumor vascularization and progression. Microcirculation. 2016;23(2):122-133.
26. Ozerdem U, Stallcup WB. Pathological angiogenesis is reduced by targeting pericytes via the Ng2 proteoglycan. Angiogenesis. 2004;7: 269-276.
27. Alliot F, Rutin J, Leenen PJ, Pessac B. Pericytes and periendothelial cells of brain parenchyma vessels co-express aminopeptidase N, aminopeptidase a, and nestin. J Neurosci Res. 1999;58:367-378.
28. Schlingemann RO, Oosterwijk E, Wesseling P, Rietveld FJ, Ruiter DJ. Aminopeptidase a is a constituent of activated pericytes in angiogenesis. J Pathol. 1996;179:436-442.
29. Kano MR, Bae Y, Iwata C, et al. Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of Tgf-beta signaling. Proc Natl Acad Sci U S A. 2007;104:3460-3465.
30. Liu AY, Ouyang G. Tumor angiogenesis: a new source of pericytes. Curr Biol. 2013;23:R565-R568.
31. Nishihara T, Remacle AG, Angert M, et al. Matrix metalloproteinase-14 both sheds cell surface neuronal glial antigen 2 (NG2) proteoglycan on macrophages and governs the response to peripheral nerve injury. J Biol Chem. 2015;290:3693-3707.
32. Zhang L, Nishihara H, Kano MR. Pericyte-coverage of human tumor vasculature and nanoparticle permeability. Biol Pharm Bull. 2012; 35:761-766.
33. Pietras K, Ostman A, Sjoquist M, et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res. 2001;61: 2929-2934.
34. Pietras K, Rubin K, Sjoblom T, et al. Inhibition of Pdgf receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res. 2002;62:5476-5484.
35. Xian X, Hakansson J, Stahlberg A, et al. Pericytes limit tumor cell metastasis. J Clin Invest. 2006;116:642-651.
36. Ruppen J, Wildhaber FD, Strub C, et al. Towards personalized medicine: chemosensitivity assays of patient lung cancer cell spheroids in a perfused microfluidic platform. Lab Chip. 2015;15:3076-3085.
37. Loi M, Marchio S, Becherini P, et al. Combined targeting of perivascular and endothelial tumor cells enhances anti-tumor efficacy of liposomal chemotherapy in neuroblastoma. J Control Release. 2010; 145:66-73.
38. Guan YY, Luan X, Xu JR, et al. Selective eradication of tumor vascular pericytes by peptide-conjugated nanoparticles for antiangiogenic therapy of melanoma lung metastasis. Biomaterials. 2014;35:3060-3070.
39. Prakash J, de Jong E, Post E, Gouw AS, Beljaars L, Poelstra K. A novel approach to deliver anticancer drugs to key cell types in tumors using a Pdgf receptor-binding cyclic peptide containing carrier. J Control Release. 2010;145:91-101.
40. Prakash J, de Jong E, Post E, Mohammad AK, Beljaars L, Poelstra K. Targeting tumor stromal cells through a PDGF-beta receptor binding carrier. J Control Release. 2010;148:e116.
41. Karen J, Rodriguez A, Friman T, Dencker L, Sundberg C, Scholz B. Effects of the histone deacetylase inhibitor valproic acid on human pericytes in vitro. PLoS One. 2011;6:e24954.
42. Murphy EA, Shields DJ, Stoletov K, et al. Disruption of angiogenesis and tumor growth with an orally active drug that stabilizes the inactive state of Pdgfrbeta/B-Raf. Proc Natl Acad Sci U S A. 2010;107: 4299-4304.
43. Chute JP, Himburg HA. Imatinib tackles lymphoma via the PDGFRβ+ pericyte. Blood. 2013;121:5107-5108.
44. Manley PW, Cowan-Jacob SW, Buchdunger E, et al. Imatinib: a selective tyrosine kinase inhibitor. Eur J Cancer. 2002;38 Suppl 5:S19-S27.
45. Miljkovic-Licina M, Hammel P, Garrido-Urbani S, et al. Targeting olfactomedin-like 3 inhibits tumor growth by impairing angiogenesis and pericyte coverage. Mol Cancer Ther. 2012;11:2588-2599.
46. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest. 2003;111:1287-1295.
47. Sennino B, Kuhnert F, Tabruyn SP, et al. Cellular source and amount of vascular endothelial growth factor and platelet-derived growth factor in tumors determine response to angiogenesis inhibitors. Cancer Res. 2009;69:4527-4536.
48. Lu C, Shahzad MM, Moreno-Smith M, et al. Targeting pericytes with a Pdgf-B aptamer in human ovarian carcinoma models. Cancer Biol Ther. 2010;9:176-182.
49. Chamorro-Jorganes A, Lee MY, Araldi E, et al. VEGF-induced expression of mir-17-92 cluster in endothelial cells is mediated by ERK/ELK1 activation and regulates angiogenesis. Circ Res. 2016;118(1):38-47.
50. Iacovelli R, Sternberg CN, Porta C, et al. Inhibition of the Vegf/Vegfr pathway improves survival in advanced kidney cancer: a systematic review and meta-analysis. Curr Drug Targets. 2015;16:164-170.
51. Gokcinar-Yagci B, Uckan-Cetinkaya D, Celebi-Saltik B. Pericytes: properties, functions and applications in tissue engineering. Stem Cell Rev. 2015;11:549-559.
52. Kim S, Lee H, Chung M, Jeon NL. Engineering of functional, perfusable 3D microvascular networks on a chip. Lab Chip. 2013;13:1489-1500.
53. He W, Nieponice A, Soletti L, et al. Pericyte-based human tissue engineered vascular grafts. Biomaterials. 2010;31:8235-8244.
54. Fuoco C, Sangalli E, Vono R, et al. 3D Hydrogel environment rejuvenates aged pericytes for skeletal muscle tissue engineering. Front Physiol. 2014;5:203.
55. Mendes LF, Pirraco RP, Szymczyk W, et al. Perivascular-like cells contribute to the stability of the vascular network of osteogenic tissue formed from cell sheet-based constructs. PLoS One. 2012;7:e41051.
56. Saik JE, Gould DJ, Watkins EM, Dickinson ME, West JL. Covalently immobilized platelet-derived growth factor-Bb promotes angiogenesis in biomimetic poly(ethylene glycol) hydrogels. Acta Biomater. 2011;7: 133-143.